Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dupixent Keeps Sanofi At Forefront Of European Pharma Growth

Hints At Raised Forecast For Blockbuster

Executive Summary

Sanofi is on a roll thanks to Dupixent and the blockbuster is providing breathing space even when some key pipeline assets are delayed.

You may also be interested in...



Sanofi's SERD Candidate Founders In Advanced Breast Cancer

The French major’s amcenestrant has missed its primary endpoint in a Phase II study of advanced breast cancer patients but could still have potential in earlier adjuvant disease.

Sanofi Hits Rare Setback For Dupixent In Urticaria

The French major has hit a rare roadblock in the onward march of its anti-inflammatory blockbuster.

Sanofi Accelerates Its ‘Carbon Neutral’ Pledge Ahead Of Climate Summit

The France-headquartered company has brought forward its carbon neutral goal, making it one of the sector’s most proactive companies.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145319

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel